PDSB

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

PDS Biotechnology Corp

NASDAQ | PDSB

1.01

USD

+$0.00

(

+0.00%

)

At Close (As of Dec 12, 2025)

$55.82M

Market Cap

-

P/E Ratio

-0.81

EPS

$2.20

52 Week High

$0.70

52 Week Low

HEALTHCARE

Sector

PDSB Chart

Recent Chart
Price Action

PDSB Technicals

Tags:

PDSB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$60K
Total Revenue $0
Cost Of Revenue $60K
Costof Goods And Services Sold $60K
Operating Income -$36M
Selling General And Administrative $13M
Research And Development $23M
Operating Expenses $36M
Investment Income Net -
Net Interest Income -$2.2M
Interest Income $2.5M
Interest Expense $4.7M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $60K
Income Before Tax -$38M
Income Tax Expense -$869K
Interest And Debt Expense -
Net Income From Continuing Operations -$38M
Comprehensive Income Net Of Tax -
Ebit -$34M
Ebitda -$34M
Net Income -$38M

Revenue & Profitability

Earnings Performance

PDSB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $45M
Total Current Assets $45M
Cash And Cash Equivalents At Carrying Value $42M
Cash And Short Term Investments $42M
Inventory -
Current Net Receivables -
Total Non Current Assets $304K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $3.4M
Other Non Current Assets -
Total Liabilities $26M
Total Current Liabilities $17M
Current Accounts Payable $1.7M
Deferred Revenue -
Current Debt -
Short Term Debt $13M
Total Non Current Liabilities $9.3M
Capital Lease Obligations $123K
Long Term Debt $9.2M
Current Long Term Debt $13M
Long Term Debt Noncurrent -
Short Long Term Debt Total $22M
Other Current Liabilities $2.8M
Other Non Current Liabilities -
Total Shareholder Equity $19M
Treasury Stock -
Retained Earnings -$182M
Common Stock $13K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$35M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $21K
Capital Expenditures $29K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$29K
Cashflow From Financing $20M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$38M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$60K
Total Revenue $0
Cost Of Revenue $60K
Costof Goods And Services Sold $60K
Operating Income -$36M
Selling General And Administrative $13M
Research And Development $23M
Operating Expenses $36M
Investment Income Net -
Net Interest Income -$2.2M
Interest Income $2.5M
Interest Expense $4.7M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $60K
Income Before Tax -$38M
Income Tax Expense -$869K
Interest And Debt Expense -
Net Income From Continuing Operations -$38M
Comprehensive Income Net Of Tax -
Ebit -$34M
Ebitda -$34M
Net Income -$38M

PDSB News

PDSB Profile

PDS Biotechnology Corp Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

PDS Biotechnology Corporation (PDSB), based in Florham Park, New Jersey, is a clinical-stage biopharmaceutical firm dedicated to advancing cancer immunotherapies via its proprietary Versamune® platform. The company is actively developing multifunctional therapies aimed at bolstering the immune response against cancers, with its lead candidate, PDS0101, currently in clinical trials targeting HPV-related malignancies. By focusing on innovative solutions that address significant unmet needs in oncology, PDSB is well-positioned to make substantial contributions to the biopharmaceutical landscape and potentially transform cancer treatment paradigms.

LPTX
+368.57%
$2.05
PAVS
-9.21%
$0.03
YGMZ
-61.42%
$0.02
KIND
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
F
+1.64%
$13.63
KVUE
0.00%
$17.32
ATPC
-20.66%
$0.14
KAVL
-23.95%
$0.15
ADAP
-15.14%
$0.05
WOK
-25.29%
$0.12
HOOD
-9.05%
$123.38
SOND
-23.45%
$0.12
RR
+12.77%
$4.68
RMBL
+60.50%
$3.21
AKAN
+25.91%
$0.99
NIO
+1.98%
$5.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
RIVN
+18.03%
$19.39
PFE
+0.07%
$25.80
SRM
+53.27%
$10.30
NVDA
-0.35%
$180.28
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AMD
+0.00%
$221.43
CDE
+9.45%
$17.48
SNAP
-3.53%
$7.64
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
ABEV
+2.04%
$2.50
TSLA
+1.92%
$455.48
FI
+2.38%
$68.16
AVGO
-9.61%
$367.30
ZDGE
+58.47%
$3.85
NOK
+2.25%
$6.36
FRMI
-39.81%
$9.17
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
AFMD
-34.94%
$0.18
UBER
+1.52%
$85.44
KO
-1.56%
$69.11
WULF
+0.44%
$15.83
SOUN
-1.47%
$12.03
CNQ
-1.72%
$33.14
VZ
+0.75%
$40.22
CLSK
+1.99%
$14.82
EXK
+4.20%
$9.41
CAN
-1.75%
$0.92
EOSE
+11.15%
$16.44
FCX
+3.57%
$48.11
TWOH
0.00%
$0.00
CGC
-1.73%
$1.13
TE
-11.92%
$5.17
DRCT
-11.02%
$0.07
MSTR
-0.72%
$183.30
VIVK
+13.10%
$0.08
GRYP
-10.38%
$1.38
PSKY
-4.07%
$14.12
IONQ
+1.70%
$52.55
MU
-1.99%
$258.46
MODV
-25.22%
$0.43
CX
+2.94%
$11.19
AMCR
+1.58%
$8.33
SLB
+1.02%
$40.34
ITUB
+2.39%
$7.27
TSLG
-2.16%
$9.92
AZI
-10.33%
$0.03
VSA
+21.72%
$0.10
PLUG
0.00%
$2.35
ROIV
+5.43%
$21.34
NVVE
-35.89%
$0.10
MDLZ
-0.18%
$53.79
NKE
+2.96%
$67.74
JOBY
+3.66%
$15.56
BTE
-1.93%
$3.04
NVTS
+0.65%
$9.18
TSM
-1.44%
$304.85
XOM
0.00%
$119.54
ASTS
+7.21%
$84.75
INTC
+0.74%
$39.80
CPNG
-0.76%
$25.86
LYFT
+0.98%
$20.52
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
OWL
-2.71%
$16.11
RXRX
-3.98%
$4.58
KHC
+0.16%
$24.39
WRBY
+2.23%
$30.23
QUBT
+2.14%
$12.83
KDP
-0.20%
$29.47
AUR
+2.44%
$4.61
ET
-0.24%
$16.41
VICI
+1.29%
$28.12
GGB
+2.24%
$3.65
NEOG
+0.85%
$7.04
AGNC
-0.77%
$10.30
LPTX
+368.57%
$2.05
PAVS
-9.21%
$0.03
YGMZ
-61.42%
$0.02
KIND
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
F
+1.64%
$13.63
KVUE
0.00%
$17.32
ATPC
-20.66%
$0.14
KAVL
-23.95%
$0.15
ADAP
-15.14%
$0.05
WOK
-25.29%
$0.12
HOOD
-9.05%
$123.38
SOND
-23.45%
$0.12
RR
+12.77%
$4.68
RMBL
+60.50%
$3.21
AKAN
+25.91%
$0.99
NIO
+1.98%
$5.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
RIVN
+18.03%
$19.39
PFE
+0.07%
$25.80
SRM
+53.27%
$10.30
NVDA
-0.35%
$180.28
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AMD
+0.00%
$221.43
CDE
+9.45%
$17.48
SNAP
-3.53%
$7.64
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
ABEV
+2.04%
$2.50
TSLA
+1.92%
$455.48
FI
+2.38%
$68.16
AVGO
-9.61%
$367.30
ZDGE
+58.47%
$3.85
NOK
+2.25%
$6.36
FRMI
-39.81%
$9.17
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
AFMD
-34.94%
$0.18
UBER
+1.52%
$85.44
KO
-1.56%
$69.11
WULF
+0.44%
$15.83
SOUN
-1.47%
$12.03
CNQ
-1.72%
$33.14
VZ
+0.75%
$40.22
CLSK
+1.99%
$14.82
EXK
+4.20%
$9.41
CAN
-1.75%
$0.92
EOSE
+11.15%
$16.44
FCX
+3.57%
$48.11
TWOH
0.00%
$0.00
CGC
-1.73%
$1.13
TE
-11.92%
$5.17
DRCT
-11.02%
$0.07
MSTR
-0.72%
$183.30
VIVK
+13.10%
$0.08
GRYP
-10.38%
$1.38
PSKY
-4.07%
$14.12
IONQ
+1.70%
$52.55
MU
-1.99%
$258.46
MODV
-25.22%
$0.43
CX
+2.94%
$11.19
AMCR
+1.58%
$8.33
SLB
+1.02%
$40.34
ITUB
+2.39%
$7.27
TSLG
-2.16%
$9.92
AZI
-10.33%
$0.03
VSA
+21.72%
$0.10
PLUG
0.00%
$2.35
ROIV
+5.43%
$21.34
NVVE
-35.89%
$0.10
MDLZ
-0.18%
$53.79
NKE
+2.96%
$67.74
JOBY
+3.66%
$15.56
BTE
-1.93%
$3.04
NVTS
+0.65%
$9.18
TSM
-1.44%
$304.85
XOM
0.00%
$119.54
ASTS
+7.21%
$84.75
INTC
+0.74%
$39.80
CPNG
-0.76%
$25.86
LYFT
+0.98%
$20.52
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
OWL
-2.71%
$16.11
RXRX
-3.98%
$4.58
KHC
+0.16%
$24.39
WRBY
+2.23%
$30.23
QUBT
+2.14%
$12.83
KDP
-0.20%
$29.47
AUR
+2.44%
$4.61
ET
-0.24%
$16.41
VICI
+1.29%
$28.12
GGB
+2.24%
$3.65
NEOG
+0.85%
$7.04
AGNC
-0.77%
$10.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.